Company intelligence / Profile preview

AnMax Bio

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

AmMax Bio is a clinical-stage biotech company developing novel therapies for cancer, with a lead monoclonal antibody (AMB-066) targeting CSF1R in Phase 2 for CRC MRD and a novel antibody-drug conjugate (AMB-101) in early development for AML. The company leverages translational expertise and a proprietary ADC platform to address significant unmet needs in oncology.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

AmgenLifeMax

Beyond the preview

Go deeper on AnMax Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnMax Bio.

Explore the full profile